Kamada (KMDA)
US Market

Kamada Stock Analysis & Ratings


KMDA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$4.22 - $6.96
Previous Close$5.43
Average Volume (3M)20.14K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-36.1
Next EarningsAug 17, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4
EPS (TTM)-0.15
Shares Outstanding44,800,504
Standard Deviation0.10
10 Day Avg. Volume34,753
30 Day Avg. Volume20,137
P/B Ratio1.25
P/S Ratio2.65
P/CF Ratio29.00
P/FCF Ratio-2.20
Total Debt$4.49M
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside109.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Kamada’s price range in the past 12 months?
Kamada lowest stock price was $4.22 and its highest was $6.96 in the past 12 months.
    What is Kamada’s market cap?
    Currently, no data Available
    What is Kamada’s price target?
    The average price target for Kamada is $11.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $11.00 ,the lowest forecast is $11.00. The average price target represents 109.13% Increase from the current price of $5.26.
      What do analysts say about Kamada?
      Kamada’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
        When is Kamada’s upcoming earnings report date?
        Kamada’s upcoming earnings report date is Aug 17, 2022 which is today.
          How were Kamada’s earnings last quarter?
          Kamada released its earnings results on May 17, 2022. The company reported -$0.037 earnings per share for the quarter, missing the consensus estimate of $0.03 by -$0.067.
            Is Kamada overvalued?
            According to Wall Street analysts Kamada’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Kamada pay dividends?
              Kamada does not currently pay dividends.
              What is Kamada’s EPS estimate?
              Kamada’s EPS estimate is -$0.02.
                How many shares outstanding does Kamada have?
                Kamada has 44,799,793 shares outstanding.
                  What happened to Kamada’s price movement after its last earnings report?
                  Kamada reported an EPS of -$0.037 in its last earnings report, missing expectations of $0.03. Following the earnings report the stock price went up 3.789%.
                    Which hedge fund is a major shareholder of Kamada?
                    Among the largest hedge funds holding Kamada’s share is ARK Investment Management LLC. It holds Kamada’s shares valued at 2M.


                      Kamada Stock Analysis

                      Smart ScoreNeutral
                      The Kamada stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description


                      Kamada Ltd. engages in the development and production of pharmaceutical products. It operates through the Proprietary Products segment and the Distribution segment. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the supply of plasma-based products for clinical use. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.

                      Similar Stocks
                      Price & Change
                      Urogen Pharma
                      Gamida Cell
                      Enlivex Therapeutics
                      Collplant Holdings

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis